Rising incidence of late stage breast cancer after COVID-19 outbreak. Real-world data from the Italian COVID-DELAY study

Autor: Giulia Mentrasti, Luca Cantini, Patrizia Vici, Nicola D'Ostilio, Nicla La Verde, Rita Chiari, Vittorio Paolucci, Sonia Crocetti, Chiara De Filippis, Federica Pecci, Francesca Sofia Di Lisa, Donatella Traisci, Maria Silvia Cona, Linda Nicolardi, Laura Pizzuti, Simona Gildetti, Simone Oldani, Arianna Della Mora, Marco Luigi Bruno Rocchi, Rossana Berardi

Publikováno v: Breast, Vol 65, Iss , Pp 164-171 (2022)

Purpose: Breast cancer (BC) patients’ (pts) management was affected by a global reorganization after Coronavirus disease 2019 (COVID-19). Our multicenter study aimed to assess the impact of COVID-19 on access to diagnosis, staging and treatment for

Externí odkaz: https://doaj.org/article/5a1c9c5ec8c048d8a0f712de03031afa

Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice

Autor: Alessandro Russo, Paolo Antonio Ascierto, Alessio Cortellini, Daniele Santini, Raffaele Giusti, Federica Zoratto, Enzo Veltri, Riccardo Marconcini, Marco Russano, Cecilia Anesi, Marco Filetti, Paolo Marchetti, Andrea Botticelli, Maria Giuseppa Vitale, Francesca Rastelli, Rita Chiari, Alain Gelibter, Giampiero Porzio, Corrado Ficorella, Domenico Mallardo, Sergio Bracarda, Claudia Bareggi, Maria Grazia Vitale, Alessandro Inno, Olga Nigro, Vincenzo Adamo, Laura Pala, Alessandro Tuzi, Enrica Teresa Tanda, Marco Tucci, Luigia Stefania Stucci, Francesco Spagnolo, Renato Bisonni, Linda Nicolardi, Nicola Petragnani, Serena Macrini, Barbara Di Cocco, David James Pinato

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)

Background Concomitant medications, such as steroids, proton pump inhibitors (PPI) and antibiotics, might affect clinical outcomes with immune checkpoint inhibitors.Methods We conducted a multicenter observational retrospective study aimed at evaluat

Externí odkaz: https://doaj.org/article/bc7575eab6cc4972af698d68589f35c5

Alarming Drop in Early Stage Colorectal Cancer Diagnoses After COVID-19 Outbreak: A Real-World Analysis from the Italian COVID-DELAY Study

Autor: Giulia Mentrasti, Luca Cantini, Clizia Zichi, Nicola D’Ostilio, Fabio Gelsomino, Erika Martinelli, Rita Chiari, Nicla La Verde, Renato Bisonni, Valeria Cognigni, Giada Pinterpe, Federica Pecci, Antonella Migliore, Giacomo Aimar, Francesca De Vita, Donatella Traisci, Andrea Spallanzani, Giulia Martini, Linda Nicolardi, Maria Silvia Cona, Maria Giuditta Baleani, Marco Luigi Bruno Rocchi, Rossana Berardi

Background Coronavirus disease 2019 (COVID-19) has triggered the disruption of health care on a global scale. With Italy tangled up in the pandemic response, oncology care has been largely diverted and cancer screenings suspended. Our multicenter Ita

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1048d3553fef9cdd1876d1384d0ccd76
https://academic.oup.com/oncolo/article/27/9/e723/6639688?login=true

Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation

Autor: Eleonora Lai, Vincenzo Di Noia, Alessio Cortellini, Giampiero Porzio, Sergio Bracarda, Alain Gelibter, Giuseppe Aprile, Bruno Vincenzi, Vincenzo Adamo, Melissa Bersanelli, Linda Nicolardi, Riccardo Marconcini, Marco Russano, Federica Zoratto, Francesca Rastelli, Mario Scartozzi, Alessandro Russo, Rita Chiari, Erika Rijavec, Clara Natoli, Massimo Di Maio, Olga Nigro, Michele Ghidini, Marta Piras, Daniele Santini, Raffaele Giusti, Francesca Simionato, Alessandro Tuzi, Sebastiano Buti, Pietro Di Marino, Davide Brocco, Alfredo Falcone, Mario Occhipinti, Stefania Gori, Fabrizio Citarella, Francesco Pantano, Enzo Veltri, Lorenzo Calvetti, Alessandro Inno, Marcello Tiseo, Marco Audisio, Michele De Tursi, Corrado Ficorella, Salvatore Intagliata, Francesco Grossi, Federica Pergolesi, Marco Filetti, Giuseppe Tonini, Paolo Bossi, Serena Macrini

Publikováno v: Cancer immunology, immunotherapy : CII. 71(4)

The prognostic relevance of early immune-related adverse events (irAEs) in patients affected by non-small cell lung cancer (NSCLC) upon immunotherapy is not fully understood. The Leading to Treatment Discontinuation cohort included 24 patients experi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf367f753863da706c958aee2ea3d29a
https://pubmed.ncbi.nlm.nih.gov/34462870

The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab

Autor: Federica Pecci, Alessio Cortellini, Valeria Cognigni, Silvia Rinaldi, Andrea Caglio, Nicoletta Ranallo, Alessio Lupi, Veronica Agostinelli, Edoardo Lenci, Corrado Ficorella, Francesco Paoloni, Rossana Berardi, Sophie Aerts, Rita Chiari, Joachim G.J.V. Aerts, Massimo Di Maio, Giulia Mentrasti, Linda Nicolardi, Luca Cantini, Anne-Marie C. Dingemans

Publikováno v: Journal of Clinical Medicine, Vol 10, Iss 1005, p 1005 (2021)
Journal of Clinical Medicine
Journal of Clinical Medicine, 10(5):1005, 1-14. Multidisciplinary Digital Publishing Institute (MDPI)
Volume 10
Issue 5

Background: The Gustave Roussy Immune (GRIm)-Score takes into account neutrophil-to-lymphocyte ratio (NLR), serum albumin concentration and lactate dehydrogenase (LDH) and its prognostic value has been investigated in patients treated with immune che

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2664c30fac510e79b9c8e5855e518094
https://www.mdpi.com/2077-0383/10/5/1005